Barclays Maintains an 'Equalweight' on Motorola Solutions (MSI); Macro Concerns Recede with Strong 3Q
Get Alerts MSI Hot Sheet
Price: $466.51 +0.32%
Rating Summary:
23 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
23 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Motorola Solutions Inc. (NYSE: MSI) price target raised $3 to $47.00.
Barclays analyst says, "Broad strength reduces concerns about a macro-driven slowdown: 3Q results were healthy-sales of $2.1bn hit the top end of the range. EPS of $0.65 beat by $0.06, including $0.02 from higher sales/opex control, $0.02 from a lower share count, and $0.02 from a 1x item. The suggestion of improving, not deteriorating, end markets allows our estimates and target to rise."
For more ratings news on Motorola Solutions Inc. click here and for the rating history of Motorola Solutions Inc. click here.
Shares of Motorola Solutions Inc. closed at $46.51 yesterday.
Barclays analyst says, "Broad strength reduces concerns about a macro-driven slowdown: 3Q results were healthy-sales of $2.1bn hit the top end of the range. EPS of $0.65 beat by $0.06, including $0.02 from higher sales/opex control, $0.02 from a lower share count, and $0.02 from a 1x item. The suggestion of improving, not deteriorating, end markets allows our estimates and target to rise."
For more ratings news on Motorola Solutions Inc. click here and for the rating history of Motorola Solutions Inc. click here.
Shares of Motorola Solutions Inc. closed at $46.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
- Barclays Downgrades PolyPeptide Group AG (PPGN:SW) to Equalweight
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share